Rankings
▼
Calendar
TGTX Q2 2024 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$73M
+357.0% YoY
Gross Profit
$65M
88.7% margin
Operating Income
$9M
12.0% margin
Net Income
$7M
9.4% margin
EPS (Diluted)
$0.04
QoQ Revenue Growth
+15.7%
Cash Flow
Operating Cash Flow
$6M
Free Cash Flow
$6M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$401M
Total Liabilities
$224M
Stockholders' Equity
$178M
Cash & Equivalents
$83M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$73M
$16M
+357.0%
Gross Profit
$65M
$14M
+360.1%
Operating Income
$9M
-$45M
+119.7%
Net Income
$7M
-$48M
+114.4%
Revenue Segments
Product
$73M
99%
Other Revenue
$682,000
1%
Royalty
$150,000
0%
License Revenue
$38,000
0%
← FY 2024
All Quarters
Q3 2024 →